On January 15, 2019, GSK announced the availability of the first authorized generic Albuterol Sulfate HFA inhaler. This inhaler is the authorized generic for GSK’s Ventolin HFA® and will continue to be manufactured by GSK and distributed by Prasco Laboratories, LLC.
- NDC 66993-0019-68: 18-g canister, 200 actuations (puffs)
As the authorized generic, it is only a substitute for Ventolin HFA®. Other albuterol HFA inhalers, including Proventil HFA® and ProAir HFA®, continue to be BX-rated and not considered equivalent.
Not to be outdone, on January 17th, 2019, Teva launched an authorized generic. This inhaler is the authorized generic for Teva Respiratory’s ProAir HFA® and will be manufactured by IVAX Pharmaceuticals (IVAX was acquired by Teva in 2006) and marketed by Teva.
- NDC 00093-3174-31: 8.5-g canister, 200 actuations (puffs)
- Prasco Albuterol HFA CAN only be substituted for Ventolin HFA®.
- Prasco Albuterol HFA CANNOT be substituted for Proventil HFA® or ProAir HFA®.
- Teva/IVAX Albuterol HFA CAN only be substituted for ProAir HFA®.
- Teva Albuterol HFA CANNOT be substituted for Proventil HFA® or Ventolin HFA®.
- Teva Albuterol HFA CANNOT be substituted for ProAir RespiClick® or ProAir Digihaler®.
- Prescriptions written for Albuterol HFA can be dispensed with whichever product is clinically appropriate or preferred on plan formulary.
- Reminder: the three brand name products are NOT substitutable and require prescriber authorization and documentation (e.g. prescription written for ProAir HFA®, but insurance prefers Ventolin HFA®).